Or Yehuda, Israel (ots/PRNewswire) - Transaction Provides Opportunity to Optimize the Significant Potential of the Cardioband[TM] Heart Valve Repair System Valtech Cardio, Ltd. (http://www.valtechcardio.com/), (Valtech), an innovator in the field of device development for mitral and tricuspid valve repair and replacement, today announced agreement to be acquired by Edwards Lifesciences Corporation (Edwards). The ...
Rheinfelden, Switzerland (ots/PRNewswire) - Tillotts Pharma AG (Switzerland) introduced a new advanced enteric coating for solid dosage forms at this year's annual meeting of the American Association of Pharmaceutical Scientists. The OPTICORE(TM) coating technology comprises two trigger systems and an accelerator to ...
Heerlen, Netherlands (ots/PRNewswire) - Over sixty universities, research institutes and companies from twenty-nine European countries will jointly study the impact of applying antimicrobial (nano-)coatings on decreasing the spread of infections. The beneficial aspects of these measures will be assessed in the context of potential environmental adverse effects, as well ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - Data reveals key findings on the tolerability of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] for patients, regardless of treatment infusion volume and rates Shire plc (LSE: SHP, NASDAQ: SHPG) will present additional data supporting the tolerability of ...
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Results from a study comparing the pharmacodynamics of Tresiba® (insulin degludec) with insulin glargine U300 in people with type 1 diabetes were presented ...
Paris (ots/PRNewswire) - - Toujeo® provides a flatter profile than insulin degludec with less within-day fluctuations - Sanofi (http://www.sanofi.com) presented today the full results of a pharmacokinetic / pharmacodynamic (PK/PD) study with Toujeo® (insulin glargine 300 Units/mL) and insulin degludec 100 Units/mL ...
Shanghai (ots/PRNewswire) - Biotherm Homme & David Beckham today invited guests on a unique digital experience to launch Biotherm Homme's #StoryOfMyLife campaign for new Force Supreme Life Essence. David Beckham and Biotherm Homme partnership to rewrite men's grooming opened new chapter in China. Journalists and ...
Lugano, Switzerland and San Diego (ots/PRNewswire) - Data to be presented on December 3, 2016; Abstract now available online Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel ...
New Orleans (ots/PRNewswire) - This material is intended for global medial media only. For journalistic assessment and preparation before publication. Abstract #T-P-3178, oral session #T-OR-2088 US study identified multiple barriers to weight management for people living with obesity Divergent perceptions and attitudes about obesity may jeopardise obesity management ...
Harare, Zimbabwe (ots/PRNewswire) - Circ MedTech (http://www.prepex.com/) Ltd., manufacturer of PrePex[TM] - the world's only non-surgical male circumcision device - donated three Mobile Clinics to the Zimbabwe Ministry of Health and Child Care with the aim to support the scale-up of Male Circumcision programs, as part of Zimbabwe's HIV Prevention strategy. (Photo: ...
Vienna (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstract: 69477 New data from the first health-related quality of life (HRQL) study related to post-meal or postprandial glucose (PPG) control, show that poor PPG control ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - If approved, avelumab, an investigational anti-PD-L1 IgG1, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma - The Marketing Authorization Application is based on Phase II data from the ...
Tokyo and Mainz, Germany (ots/PRNewswire) - - Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, "Ganymed"), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas ...
Nuremberg, Germany (ots/PRNewswire) - Internationally, the top five physical conditions that people worry most about having, either now or as they age, are eyesight getting poorer, not being as mentally alert, lacking energy, having trouble taking care of themselves physically, and being unable to walk or drive. These are the findings from a GfK survey (http://www.gfk.com/global-studies/global-study-overview/) of the ...
Richmond, British Columbia (ots/PRNewswire) - bioLytical Laboratories, a world leader in rapid infectious disease tests, is proud to have participated in the HIV Drug Therapy Congress (http://hivglasgow.org/) which just wrapped up in Glasgow. This annual Congress brought together key opinion leaders, global HIV/AIDS programme directors, researchers, physicians, community health representatives, industry and other ...
Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
Munich (ots/PRNewswire) - - Atrial fibrillation (AF) increases the risk of a severe stroke,[1] however almost half of patients are unaware of the risk[2] - The AFfect survey revealed that one in two patients had not heard of the condition at time of diagnosis[2] - World Stroke Day is on Saturday 29th October, find ...
Recife, Brazil (ots/PRNewswire) - (Logo: http://photos.prnewswire.com/prnh/20161024/431955LOGO ) 25 leading research and public health organizations from Latin America, North America, Africa, Asia, and Europe gathered in Recife for the launch of ZikaPLAN (Zika Preparedness Latin American Network). This global ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - Labeling Update Based on Maintenance of Efficacy Data from a 38-Week Phase 3 Study For U.S. Audiences Only - Shire plc (LSE: SHP, NASDAQ: SHPG) announces an update to the Vyvanse® (lisdexamfetamine dimesylate) labeling to include information regarding the approval of a ...
London (ots/PRNewswire) - New easy-to-use software designed to improve the planning of 90Y selective internal radiation therapy (SIRT) treatment for patients with liver cancer BTG plc (LSE: BTG), an international specialist healthcare company, with Mirada Medical Ltd, a leading global brand in medical imaging ...
Munich (ots/PRNewswire) - - Three abstracts highlight the economic burden of Venous Thromboembolism (VTE) in Europe and provide new insights into VTE treatment with LIXIANA®(edoxaban) - Daiichi Sankyo is committed to enhancing the understanding, prevention and treatment of VTE, and is partnering with the ...
Tokyo (ots/PRNewswire) - Acquisition strengthens global HOYA Vision Care business HOYA Corporation (HOYA) today announced a definitive agreement to acquire Performance Optics, LLC (Performance Optics), including its subsidiaries VISION EASE and Daemyung Optical. Performance Optics is a global ophthalmic lens manufacturer specializing in polycarbonate, photochromic, ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Grant established by Merck KGaA, Darmstadt, Germany, recognizes pioneering research in personalized treatment of solid tumors - Winners selected by internationally renowned oncologists from 405 applications representing 49 countries Merck KGaA, ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or UK-based media - Grant established by Merck recognizes pioneering research in personalized treatment of solid tumors - Winners selected by internationally renowned oncologists from 405 applications representing 49 countries Merck, a leading science and technology company, today announced the recipients of ...
Lugano, Switzerland (ots/PRNewswire) - ~ Helsinn Group creates new investment fund in 40th anniversary year ~ ~ The new fund will focus on supporting early-stage investment opportunities in areas of high unmet patient need ~ Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, today introduces Helsinn Investment Fund S.A. ("the Fund"), a fund focused on early-stage investment opportunities in ...
Rheinfelden, Switzerland (ots/PRNewswire) - Zeria Pharmaceutical Co., Ltd. has received the approval for a new drug application for Zentacort 3mg capsules from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the indication of the improvement of Crohn's Disease (CD). Following the acquisition of the ...
Paris and Singapore (ots/PRNewswire) - Cancer researchers from Assistance Publique - Hôpitaux de Paris (AP-HP) and The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cancer Centre Singapore (NCCS) and Singapore Clinical Research Institute (SCRI) announced that they will collaborate on a ...
Shire Pharmaceuticals Group Plc
Lexington, Massachusetts (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) has issued their decision upholding the validity of U.S. Patent No. 6,773,720, related to Shire's LIALDA® (mesalamine) product. The petition seeking to institute inter partes review (IPR) was ...
London (ots/PRNewswire) - Following the acquisitions of Invent Farma and neuraxpharm (the "Group") by funds advised by Apax Partners, Stephan Walz has been appointed Chief Executive Officer. He will assume the newly-created role of Group CEO and will be leading Invent Farma's and neuraxpharm's activities across all markets. Until 2015 Mr Walz was the CEO of Aristo, a Germany-headquartered, multi-country pharmaceutical ...
Munich (ots/PRNewswire) - Results highlight the benefits of reduced dose edoxaban compared to warfarin in a potentially higher risk venous thromboembolism (VTE) patient population[1] Daiichi Sankyo Europe GmbH (hereafter Daiichi Sankyo) today announced data from a new analysis of the phase 3 Hokusai-VTE study, which ...